Immunogenicity of influenza A(H1N1)pdm09 vaccine in patients with diabetes mellitus: With special reference to age, body mass index, and HbA1c

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 5, 2014, Pages 1187-1194

  Egawa, Yumi ^a   Ohfuji, Satoko ^a   Fukushima, Wakaba ^a   Yamazaki, Yuko ^a   Morioka, Tomoaki ^a   Emoto, Masanori ^a   Maeda, Kazuhiro ^b   Inaba, Masaaki ^a   Hirota, Yoshio ^a  

^a Osaka Prefecture University   (Japan)

^b The Research Foundation for Microbial Diseases of Osaka University   (Japan)

Author keywords

Age; BMI; Diabetes mellitus; HbA1c; Immunogenicity; Influenza A(H1N1)pdm09 vaccine; Predictors

Indexed keywords

HEMOGLOBIN A1C; INFLUENZA VACCINE; INSULIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGE; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BODY MASS; CLINICAL ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; SEROCONVERSION; UNSPECIFIED SIDE EFFECT; AGING; DRUG EFFECTS; GENETICS; IMMUNOGENETICS; IMMUNOLOGY; INFLUENZA, HUMAN; MIDDLE AGED; PHYSIOLOGY;

AGED; AGING; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMMUNOGENETIC PHENOMENA; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84901428858     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28252     Document Type: Article

References (32)

1. Smith SA, Poland GA. Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care 2000; 23:95-108; PMID:10857977; http://dx.doi.org/10.2337/diacare.23.1.95
2. Simonsen L, Fukuda K, Schonberger LB, Cox NJ. The impact of influenza epidemics on hospitalizations. J Infect Dis 2000; 181:831-7; PMID:10720501; http://dx.doi.org/10.1086/315320
3. Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, Rutten GE. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41:281-8; PMID:16007521; http://dx.doi.org/10.1086/431587
4. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46(RR-9):1-25; PMID:9148134
5. Smith SA, Poland GA; American Diabetes Association. Influenza and pneumococcal immunization in diabetes. Diabetes Care 2004; 27(Suppl 1):S111-3; PMID:14693944; http://dx.doi.org/10.2337/diacare.27.2007.S111
6. New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 2009; 84:249-57; PMID:19537358.
7. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-13; PMID:19745216; http://dx.doi.org/10.1056/NEJMoa0907413
8. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325:197-201; PMID:19465683; http://dx.doi.org/10.1126/science.1176225
9. Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, Li RC, Xia SL, Zhao YL, Li FJ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375:56-66; PMID:20018364; http://dx.doi.org/10.1016/S0140- 6736(09)62003-1
10. Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, Zhang XF, Pan HX, Meng FY, Hu YM, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361: 2414-23; PMID:19846844; http://dx.doi.org/10.1056/ NEJMoa0908535
11. Ohfuji S, Fukushima W, Tamori A, Maeda K, Maeda A, Hirota Y. Immunogenicity of influenza A(H1N1)pdm09 vaccine and the associated factors on lowered immune response in patients with hepatitis C. Influenza Other Respir Viruses 2013; 7:456-65; PMID:22897938; http://dx.doi.org/10.1111/j.1750-2659. 2012.00424.x
12. Kao TM, Hsieh SM, Kung HC, Lee YC, Huang KC, Huang LM, Chang FY, Wang NC, Liu YC, Lee WS, et al. Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. Vaccine 2010; 28:6159-63; PMID:20659517; http://dx.doi.org/10.1016/j.vaccine.2010.07.026
13. Hui SL, Chu LW, Peiris JS, Chan KH, Chu D, Tsui W. Immune response to influenza vaccination in community-dwelling Chinese elderly persons. Vaccine 2006; 24:5371-80; PMID:16713661; http://dx.doi.org/10.1016/j.vaccine.2006.04.032
14. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-69; PMID:16213065; http://dx.doi.org/10.1016/j.vaccine.2005.08.105
15. Fülöp T Jr., Wagner JR, Khalil A, Weber J, Trottier L, Payette H. Relationship between the response to influenza vaccination and the nutritional status in institutionalized elderly subjects. J Gerontol A Biol Sci Med Sci 1999; 54:M59-64; PMID:10051856; http://dx.doi.org/10.1093/gerona/54.2. M59
16. Bellei NC, Carraro E, Castelo A, Granato CF. Risk factors for poor immune response to influenza vaccination in elderly people. The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases 2006; 10:269-73.
17. Hara M, Tanaka K, Hirota Y. Immune response to influenza vaccine in healthy adults and the elderly: association with nutritional status. Vaccine 2005; 23:1457-63; PMID:15670881; http://dx.doi.org/10.1016/j.vaccine.2004.09.022
18. Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 2004; 172:3437-46; PMID:15004143
19. Kang I, Hong MS, Nolasco H, Park SH, Dan JM, Choi JY, Craft J. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol 2004; 173:673-81; PMID:15210831
20. Saurwein-Teissl M, Lung TL, Marx F, Gschösser C, Asch E, Blasko I, Parson W, Böck G, Schönitzer D, Trannoy E, et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 2002; 168:5893-9; PMID:12023394
21. Sagawa M, Kojimahara N, Otsuka N, Kimura M, Yamaguchi N. Immune response to influenza vaccine in the elderly: association with nutritional and physical status. Geriatr Gerontol Int 2011; 11:63-8; PMID:20738411; http://dx.doi.org/10. 1111/j.1447-0594.2010.00641.x
22. Delespesse G, Duchateau J, Bastenie PA, Lauvaux JP, Collet H, Govaerts A. Cell-mediated immunity in diabetes mellitus. Clin Exp Immunol 1974; 18:461-7; PMID:4283119
23. Pozzilli P, Gale EA, Visalli N, Baroni M, Crovari P, Frighi V, Cavallo MG, Andreani D. The immune response to influenza vaccination in diabetic patients. Diabetologia 1986; 29:850-4; PMID:3569690; http://dx.doi.org/10.1007/ BF00870139
24. Nam JS, Kim AR, Yoon JC, Byun Y, Kim SA, Kim KR, Cho S, Seong BL, Ahn CW, Lee JM. The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with Type 2 diabetes mellitus in Korea. Diabetic medicine: a journal of the British Diabetic Association 2011; 28:815-7.
25. Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics 2006; 118:e579-85; PMID:16950949; http://dx.doi.org/10. 1542/peds.2006-0201
26. Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 2006; 194:1032-9; PMID:16991077; http://dx.doi.org/10.1086/507309
27. Parkman PD, Hopps HE, Rastogi SC, Meyer HM Jr. Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 1977; 136(Suppl):S722-30; PMID:606797; http://dx.doi.org/10.1093/infdis/136.Supplement-3.S722
28. Sencer DJ, Millar JD. Reflections on the 1976 swine flu vaccination program. Emerg Infect Dis 2006; 12:29-33; PMID:16494713; http://dx.doi.org/10. 3201/eid1201.051007
29. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-51; PMID:16571878; http://dx.doi.org/10.1056/NEJMoa055778
30. Jackson LA, Chen WH, Stapleton JT, Dekker CL, Wald A, Brady RC, Edupuganti S, Winokur P, Mulligan MJ, Keyserling HL, et al. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis 2012; 206:811-20; PMID:22782949; http://dx.doi.org/10.1093/infdis/jis427
31. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35; PMID:19745215; http://dx.doi.org/10. 1056/NEJMoa0907650
32. Hirst GK. The Quantitative Determination of Influenza Virus and Antibodies by Means of Red Cell Agglutination. J Exp Med 1942; 75:49-64; PMID:19871167; http://dx.doi.org/10.1084/jem.75.1.49